BJUI Mini Reviews - A new patient-focused approach to the treatment of metastatic renal cell carcinoma: Establishing customized treatment options

BERKELEY, CA ( - Randomized controlled trials (RCTs) show that six targeted agents – sorafenib, sunitinib, temsirolimus, everolimus, bevacizumab and pazopanib – improve outcome in advanced renal cell carcinoma (RCC).

The populations enrolled in the pivotal phase III studies differed, and, to date, no head-to-head comparisons allow us to judge relative efficacy and tolerability. Populations recruited to RCTs under-represent certain patient subtypes, notably the elderly and those with comorbidities. Choosing the agent most appropriate in a specific case requires that we take into account the characteristics of the patient, the nature of their disease, and the history and aims of therapy. Data from expanded access programmes and clinical experience may be as relevant as the results of RCTs when making this difficult decision. To show how different sources of data can be integrated, we propose a schema that acknowledges nine patient-, disease-, and treatmentrelated factors relevant to clinical decisionmaking and provides an easily understood visual indication of the strength with which a particular agent can be recommended for use in specific subgroups of patients. As an example, we show how this tool shows the suitability of sorafenib in RCC subpopulations of differing age, prognosis, performance status, tumour burden and distribution, treatment history, and comorbidity. This patient-focused approach has broad application to other agents and tumour types...View or save the Mini Review as a .pdf file


Joaquim Bellmunt, Tim Eisen*, Cezary Szczylik, Peter Mulders, and Camillo Porta§

Medical Oncology Service, University Hospital del Mar, Barcelona, Spain, *University of Cambridge, Department of Oncology, Addenbrooke’s Hospital, Cambridge, UK, Central Clinical Hospital, Military Institute of Medicine, Warsaw, Poland, Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands, and  §Laboratory of Pre-Clinical Oncology and Developmental Therapeutics, Medical Oncology, IRCCS San Matteo University Hospital Foundation, Pavia, Italy


More BJUI Mini Reviews and Archives